Novel polymeric nanoparticles for intracellular delivery of peptide cargos: Antitumor efficacy of the BCL-2 conversion peptide NuBCP-9

Cancer Research

Volumn 74, Issue 12, 2014, Pages 3271-3281

  Kumar, Manoj ^a   Gupta, Dikshi ^a   Singh, Gurpal ^a   Sharma, Sapna ^a   Bhat, Madhusudan ^b   Prashant, C K ^b   Dinda, A K ^b   Kharbanda, Surender ^c   Kufe, Donald ^c   Singh, Harpal ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG CARRIER; MACROGOL; NANOPARTICLE; NUBCP 9 PEPTIDE; POLOXAMER; POLYLACTIC ACID; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL KILLING; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EHRLICH ASCITES TUMOR; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN TRANSPORT; SUSTAINED DRUG RELEASE; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, EHRLICH TUMOR; CELL PROLIFERATION; DELAYED-ACTION PREPARATIONS; DRUG SCREENING ASSAYS, ANTITUMOR; HEP G2 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LACTATES; MCF-7 CELLS; MICE; MICE, INBRED BALB C; NANOCAPSULES; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; PROPYLENE GLYCOLS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR BURDEN;

EID: 84902188616     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2015     Document Type: Article

References (50)

1. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-607. (Pubitemid 38028528)
2. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004;305:626-9. (Pubitemid 39006738)
3. Pitter K, Bernal F, Labelle J, Walensky LD. Dissection of the BCL-2 family signaling network with stabilized α-helices of BCL-2 domains. Methods Enzymol 2008;446:387-408.
4. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-81. (Pubitemid 40825512)
5. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-8.
6. Kolluri SK, Zhu X, Zhou X, Lin B, Chen Y, Sun K, et al. A short Nur77-derived peptide converts Bcl-2 from a protector to a killer. Cancer Cell 2008;14:285-98.
7. Lin B, Kolluri SK, Lin F, Liu W, Han YH, Cao X, et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004;116:527-40. (Pubitemid 38264430)
8. Bidwell GL 3rd, Raucher D. Therapeutic peptides for cancer therapy. Part I - peptide inhibitors of signal transduction cascades. Expert Opin Drug Deliv 2009;6:1033-47.
9. Raucher D, Moktan S, Massodi I, Bidwell GL 3rd. Therapeutic peptides for cancer therapy. Part II - cell cycle inhibitory peptides and apoptosis-inducing peptides. Expert Opin Drug Deliv 2009;6:1049-64.
10. Talmadge JE. Pharmacodynamic aspects of peptide administration biological response modifiers. Adv Drug Deliv Rev 1998;33:241-52. (Pubitemid 28403626)
11. Fischer PM. Cellular uptake mechanisms and potential therapeutic utility of peptidic cell delivery vectors: progress 2001-2006. Med Res Rev 2007;27:755-95. (Pubitemid 350035119)
12. Grdisa M. The delivery of biologically active (therapeutic) peptides and proteins into cells. Curr Med Chem 2011;18:1373-9.
13. Li H, Nelson CE, Evans BC, Duvall CL. Delivery of intracellular-acting biologics in pro-apoptotic therapies. Curr Pharm Des 2011;17:293-319.
14. Gu Z, Biswas A, Zhao M, Tang Y. Tailoring nanocarriers for intracellular protein delivery. Chem Soc Rev 2011;40:3638-55.
15. Watkins CL, Sayers EJ, Allender C, Barrow D, Fegan C, Brennan P, et al. Co-operative membrane disruption between cell-penetrating peptide and cargo: implications for the therapeutic use of the Bcl-2 converter peptide D-NuBCP-9-r8. Mol Ther 2011;19:2124-32.
16. Kratz F, Warnecke A. Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems. J Control Release 2012;164:221-35.
17. Manzoor AA, Lindner LH, Landon CD, Park JY, Simnick AJ, Dreher MR, et al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res 2012;72:5566-75.
18. Zhang XY, Chen J, Zheng YF, Gao XL, Kang Y, Liu JC, et al. Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo. Cancer Res 2009;69:6506-14.
19. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012;41:2971-3010.
20. Xiao RZ, Zeng ZW, Zhou GL, Wang JJ, Li FZ, Wang AM. Recent advances in PEG-PLA block copolymer nanoparticles. Int J Nanomedicine 2010;5:1057-65.
21. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004;10:3708-16. (Pubitemid 38697604)
22. Xiong XY, Li QH, Li YP, Guo L, Li ZL, Gong YC. Pluronic P85/poly(lactic acid) vesicles as novel carrier for oral insulin delivery. Colloids Surf B Biointerfaces 2013;111C:282-8.
23. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J 2002;16:1217-26. (Pubitemid 34815409)
24. Doiron AL, Chu K, Ali A, Brannon-Peppas L. Preparation and initial characterization of biodegradable particles containing gadolinium-DTPA contrast agent for enhanced MRI. Proc Natl Acad Sci U S A 2008;105:17232-7.
25. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 2012;14:1-16.
26. Andersson SR, Hakkarainen M, Inkinen S, Sodergard A, Albertsson AC. Customizing the hydrolytic degradation rate of stereocomplex PLA through different PDLA architectures. Biomacromolecules 2012;13:1212-22.
27. Hoglund A, Odelius K, Albertsson AC. Crucial differences in the hydrolytic degradation between industrial polylactide and laboratory-scale poly(L-lactide). ACS Appl Mater Interfaces 2012;4:2788-93.
28. Nathan B, Gusterson B, Jadayel D, O'Hare M, Anbazhagan R, Jayatilake H, et al. Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotype. For the International (Ludwig) Breast Cancer Study Group. Ann Oncol 1994;5:409-14. (Pubitemid 24159644)
29. Tan J,Wang B, Zhu L. Regulation of survivin and Bcl-2 in HepG2 cell apoptosis induced by quercetin. Chem Biodivers 2009;6:1101-10.
30. Bhattacharyya A, Choudhuri T, Pal S, Chattopadhyay S, K Datta G, Sa G, et al. Apoptogenic effects of black tea on Ehrlich's ascites carcinoma cell. Carcinogenesis 2003;24:75-80. (Pubitemid 36193197)
31. Turner PV, Brabb T, Pekow C, Vasbinder MA. Administration of substances to laboratory animals: routes of administration and factors to consider. J Am Assoc Lab Anim Sci 2011;50:600-13.
32. Verdine GL, Walensky LD. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin Cancer Res 2007;13:7264-70.
33. Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005;7:457-68. (Pubitemid 40719129)
34. Sarafraz-Yazdi E, Bowne WB, Adler V, Sookraj KA, Wu V, Shteyler V, et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proc Natl Acad Sci U S A 2010;107:1918-23.
35. Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, et al. Direct inhibition of the NOTCH transcription factor complex. Nature 2009;462:182-8.
36. Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, et al. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther 2011;10:806-16.
37. Grossmann TN, Yeh JT, Bowman BR, Chu Q, Moellering RE, Verdine GL. Inhibition of oncogenic Wnt signaling through direct targeting of beta-catenin. Proc Natl Acad Sci U S A 2012;109:17942-7.
38. Stewart ML, Fire E, Keating AE, Walensky LD. The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat Chem Biol 2010;6:595-601.
39. Ko YT, Falcao C, Torchilin VP. Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy. Mol Pharm 2009;6:971-7.
40. Adar L, Shamay Y, Journo G, A D. Pro-apoptic peptide-polymer conjugates to induce mitochondrial-dependent cell death. Polym Adv Technol 2010;22:199-208.
41. Soman NR, Baldwin SL, Hu G, Marsh JN, Lanza GM, Heuser J, et al. Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing cell growth. J Clin Invest 2009;119:2830-42.
42. Schluep T, Gunawan P, Ma L, Jensen GS, Duringer J, Hinton S, et al. Polymeric tubulysin-peptide nanoparticles with potent antitumor activity. Clin Cancer Res 2009;15:181-9.
43. Kim SK, Huang L. Nanoparticle delivery of a peptide targeting EGFR signaling. J Control Release 2012;157:279-86.
44. Tomar L, Tyagi C, Kumar M, Kumar P, Singh H, Choonara YE, et al. In vivo evaluation of a conjugated poly(lactide-ethylene glycol) nanoparticle depot formulation for prolonged insulin delivery in the diabetic rabbit model. Int J Nanomedicine 2013;8:505-20.
45. Essa S, Rabanel JM, Hildgen P. Effect of polyethylene glycol (PEG) chain organization on the physicochemical properties of poly(D, Llactide) (PLA) based nanoparticles. Eur J Pharm Biopharm 2010;75:96-106.
46. Feng R, Song Z, Zhai G. Preparation and in vivo pharmacokinetics of curcumin-loaded PCL-PEG-PCL triblock copolymeric nanoparticles. Int J Nanomedicine 2012;7:4089-98.
47. Hans M,Lowman A. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 2002;6:319-27. (Pubitemid 36238389)
48. Wang B, Jiang W, Yan H, Zhang X, Yang L, Deng L, et al. Novel PEG-graft-PLA nanoparticles with the potential for encapsulation and controlled release of hydrophobic and hydrophilic medications in aqueous medium. Int J Nanomedicine 2011;6:1443- 51.
49. Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012;4:128ra39.
50. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 2006;103:6315-20.